News
Public · Published
Merck & Company, Inc. Stock 12‑Month Price Target Raised to $162.25, Implies 12% Upside
Analysts' average 12-month price target for Merck & Company, Inc. rose from $160.56 to $162.25. Based on the Nov. 3 closing price, the revised target implies approximately 12% potential upside. The consensus rating remains Buy among 30 analysts, with 21 Buys, eight Holds and one Sell.
Published:
Updated:
What happened
Analysts’ average 12-month price target for Merck & Company, Inc. rose from $160.56 to $162.25. Based on the Nov. 3 closing price, the revised target implies approximately 12% potential upside. The consensus rating remains Buy among 30 analysts, with 21 Buys, eight Holds and one Sell.
Confirmed
Global impact / market context
The higher target signals a modest improvement in analysts’ expected value for Merck shares, but it is a forecast rather than a promised return. If investors act on the more positive view, buying could support the share price; the article provides no evidence of changed company sales or costs.
Analyst inference
The 24 analysts’ average target is $162.25, while individual forecasts span $105 to $186 per share, showing considerable disagreement. The separate rating count covers 30 analysts and remains Buy overall; these views describe expectations, not confirmed changes in Merck’s business or financial results.
Confirmed
What to watch
- Check whether later analyst updates raise or lower the average target, and whether forecast changes cite concrete revisions to expected sales, costs, or earnings. Analyst inference
- Compare the share price with the $162.25 average target and the Nov. 3 closing-price reference; the stated 12% upside is tied to that reference point. Confirmed
- Watch for changes in the 30-analyst rating mix—currently 21 Buys, eight Holds and one Sell—to see whether the overall Buy consensus strengthens or weakens. Analyst inference
Evidence
- Original source link unavailable